BRIEF—Astellas to sell Dutch plant to Delpharm

Japanese drug major Astellas Pharma said today that its Dutch subsidiaries have made an intended decision to sell and transfer its manufacturing plant, located in Meppel, Netherlands, to Delpharm Industrie SAS.

The definitive agreement will be executed after completing works council consultation and local legal and regulatory requirements.

Upon the transfer of the business to Delpharm, the plan is that Delpharm will continue to manufacture the products that are currently manufactured at the plant in Meppel and will deliver these products to Astellas group to ensure the stable supply of products for patients.

Financial terms of the transaction, including the purchase price, are not disclosed